Cargando…

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects

CONTEXT: Metastatic medullary thyroid carcinoma (MTC) and radioactive iodine–refractory differentiated thyroid carcinoma (RAI-R DTC) have poor prognosis and limited treatment options. Selpercatinib (LOXO-292), a selective kinase inhibitor targeting the RET gene, has shown a 69% to 79% objective resp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsang, Venessa, Gill, Anthony, Gild, Matti, Lurie, Brett, Blumer, Lucy, Siddall, Rhonda, Clifton-Bligh, Roderick, Robinson, Bruce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Online Only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387698/ https://www.ncbi.nlm.nih.gov/pubmed/35647935 http://dx.doi.org/10.1210/clinem/dgac337

Ejemplares similares

Clinical Activity of Selpercatinib in RET Mutant Pheochromocytoma-Case Reports
por: Konda, Bhavana, et al.
Publicado: (2021)

Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge
por: Gild, Matti L, et al.
Publicado: (2022)

Response to Letter to the Editor: “Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes”
por: Tsang, Venessa H M, et al.
Publicado: (2020)

Infiltrative lymphocytic hypophysitis successfully treated with rituximab and mycophenolate mofetil
por: Lin, Mike, et al.
Publicado: (2020)

Destabilizing RET in targeted treatment of thyroid cancers
por: Gild, M L, et al.
Publicado: (2015)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Surveillance Improves Outcomes for Carriers of SDHB Pathogenic Variants: A Multicenter Study
por: Davidoff, Dahlia F, et al.
Publicado: (2022)

Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma
por: Kesby, Nicholas, et al.
Publicado: (2023)

Immune Related Adverse Events of the Thyroid – A Narrative Review
por: Muir, Christopher A., et al.
Publicado: (2022)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Medullary Thyroid Cancer: Updates and Challenges
por: Gild, Matti L, et al.
Publicado: (2023)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
por: Ortiz, Michael V., et al.
Publicado: (2020)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

Lobectomy and completion thyroidectomy rates increase after the 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines update
por: Worrall, Benjamin J, et al.
Publicado: (2023)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors
por: Muir, Christopher Alan, et al.
Publicado: (2021)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
por: Porcelli, Tommaso, et al.
Publicado: (2023)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Translational Utility of Liquid Biopsies in Thyroid Cancer Management
por: Wijewardene, Ayanthi A., et al.
Publicado: (2021)

Development of a novel clinical support tool for active surveillance of low risk papillary thyroid cancer
por: White, Eleanor, et al.
Publicado: (2023)

Cohort Profile: The Porton Down Veterans cohort study
por: Archer, Gemma, et al.
Publicado: (2022)

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer
por: Wirth, Lori J, et al.
Publicado: (2022)

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
por: Shen, Tao, et al.
Publicado: (2021)

Cohort Profile Update: The British Regional Heart Study 1978–2018: 40 years of follow-up of older British men
por: Kimble, Rachel, et al.
Publicado: (2022)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis
por: Fuchs, Talia L., et al.
Publicado: (2020)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
por: d'Arienzo, Paolo D., et al.
Publicado: (2023)

Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer
por: Rolfo, C., et al.
Publicado: (2022)

Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
por: Arora, Aakriti, et al.
Publicado: (2023)

Early-Pregnancy Intermediate Hyperglycemia and Adverse Pregnancy Outcomes Among Women Without Gestational Diabetes
por: Ye, Yunzhen, et al.
Publicado: (2021)

Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report
por: Scattolin, Daniela, et al.
Publicado: (2023)

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

Thyroid Hormone Abuse Among Elite Athletes
por: Handelsman, David J, et al.
Publicado: (2023)

The Medical Research Council (UK)/Uganda Virus Research Institute Uganda Research Unit on AIDS – ‘25 years of research through partnerships’
por: Kaleebu, P, et al.
Publicado: (2015)

Cognitive Function of Children and Adolescents With Congenital Adrenal Hyperplasia: Importance of Early Diagnosis
por: Messina, Valeria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lhrrqmp180jmvcv6i04t2gi1qb